<DOC>
	<DOCNO>NCT02514174</DOCNO>
	<brief_summary>Continuos treatment progression occurence intolerable Adverse Event ( AE ) end trial . The end trial one year last patient enter study .</brief_summary>
	<brief_title>Afatinib Treatment Patients With EGFR Mutation Positive NSCLC Who Are Age 70 Older</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologically cytologically confirm NSCLC 2 . Stage IV Cancer ( include cytologically proven pleural effusion pericardial effusion ) recurrent disease . The stag base American Joint Commitee Cancer ( AJCC ) Classification Malignant Tumours ( TNM ) 7th edition ( R124710 ) 3 . Evidence common EGFR mutation ( Del 19 and/or L858R ) 4 . Age = 70 year 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 ( R01 0787 ) 6 . No prior systemic therapy metastatic recurrent NSCLC . Further inclusion criterion apply . Exclusion criterion : 1 . Prior participation afatinib clinical study , even assign afatinib treatment 2 . Concurrent investigational therapy investigational therapy within 4 week start afatinib therapy 3 . Radiotherapy within 4 week prior start study treatment , except follow : . ) Palliative radiation target organ chest may allow 2 week prior study treatment , ii . ) Single dose palliative treatment symptomatic metastasis outside allowance discuss sponsor prior enrol . 4 . Major surgery within 4 week start study treatment schedule surgery project course study 5 . Systemic chemotherapy , biological therapy , immunotherapy investigational agent within 5 halflife drug within four week prior start afatinib treatment ( halflife drug unknown ) . 6 . Men , capable father child , unwilling use adequate contraception prior study entry , duration study participation , least 28 day treatment end . Further Exclusion Criteria Apply .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>